EP1583823A4 - Isolement et identification de lymphocytes t a reactivite croisee - Google Patents

Isolement et identification de lymphocytes t a reactivite croisee

Info

Publication number
EP1583823A4
EP1583823A4 EP03800185A EP03800185A EP1583823A4 EP 1583823 A4 EP1583823 A4 EP 1583823A4 EP 03800185 A EP03800185 A EP 03800185A EP 03800185 A EP03800185 A EP 03800185A EP 1583823 A4 EP1583823 A4 EP 1583823A4
Authority
EP
European Patent Office
Prior art keywords
reactive
isolation
cells
identification
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03800185A
Other languages
German (de)
English (en)
Other versions
EP1583823A2 (fr
Inventor
Jingwu Z Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of EP1583823A2 publication Critical patent/EP1583823A2/fr
Publication of EP1583823A4 publication Critical patent/EP1583823A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP03800185A 2002-12-31 2003-12-23 Isolement et identification de lymphocytes t a reactivite croisee Withdrawn EP1583823A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43736902P 2002-12-31 2002-12-31
US437369P 2002-12-31
PCT/US2003/041284 WO2004060145A2 (fr) 2002-12-31 2003-12-23 Isolement et identification de lymphocytes t a reactivite croisee

Publications (2)

Publication Number Publication Date
EP1583823A2 EP1583823A2 (fr) 2005-10-12
EP1583823A4 true EP1583823A4 (fr) 2006-02-22

Family

ID=32713173

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03800185A Withdrawn EP1583823A4 (fr) 2002-12-31 2003-12-23 Isolement et identification de lymphocytes t a reactivite croisee

Country Status (4)

Country Link
US (2) US20060204495A1 (fr)
EP (1) EP1583823A4 (fr)
AU (1) AU2003299914A1 (fr)
WO (1) WO2004060145A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585462A1 (fr) 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methodes de generation de cellules t de regulation cd4+cd25+ specifiques a un antigene, compositions et methodes d'utilisation associees
WO2008026927A2 (fr) * 2006-08-30 2008-03-06 Academisch Medisch Centrum Procédé d'affichage des répertoires des récepteurs des lymphocytes t et b
WO2008059252A2 (fr) * 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Procédés et composition de récepteurs des lymphocytes t qui reconnaissent l'antigène 5t4
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US20130040375A1 (en) * 2011-08-08 2013-02-14 Tandem Diagnotics, Inc. Assay systems for genetic analysis
US8700338B2 (en) 2011-01-25 2014-04-15 Ariosa Diagnosis, Inc. Risk calculation for evaluation of fetal aneuploidy
US10533223B2 (en) 2010-08-06 2020-01-14 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US20130261003A1 (en) 2010-08-06 2013-10-03 Ariosa Diagnostics, In. Ligation-based detection of genetic variants
EP3731860A1 (fr) 2017-12-29 2020-11-04 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Compositions et méthodes de traitement d'une maladie auto-immune

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013904A1 (fr) * 1997-09-19 1999-03-25 University Of Southern California Vaccination a l'aide de lymphocytes t pour le traitement de la sclerose en plaques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
PL364917A1 (en) * 1999-02-23 2004-12-27 Baylor College Of Medicine T cell receptor vbeta-dbeta-jbeta sequence and methods for its detection
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013904A1 (fr) * 1997-09-19 1999-03-25 University Of Southern California Vaccination a l'aide de lymphocytes t pour le traitement de la sclerose en plaques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
STINISSEN P ET AL: "Vaccination with autoreactive T cell clones in multiple sclerosis: Overview of immunological and clinical data", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 45, no. 4, 15 August 1996 (1996-08-15), pages 500 - 511, XP002091572, ISSN: 0360-4012 *
STINISSEN PIET ET AL: "gammadelta T cell responses to activated T cells in multiple sclerosis patients induced by T cell vaccination", JOURNAL OF NEUROIMMUNOLOGY, vol. 87, no. 1-2, 1 July 1998 (1998-07-01), pages 94 - 104, XP002360473, ISSN: 0165-5728 *
TEJADA-SIMON MARIA V ET AL: "Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis.", ANNALS OF NEUROLOGY. FEB 2003, vol. 53, no. 2, February 2003 (2003-02-01), pages 189 - 197, XP002360481, ISSN: 0364-5134 *
ZHANG J ET AL: "MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 261, no. 5127, 10 September 1993 (1993-09-10), pages 1451 - 1454, XP002091570, ISSN: 0036-8075 *
ZHANG J ET AL: "T cell vaccination: Clinical application in autoimmune diseases", JOURNAL OF MOLECULAR MEDICINE, SPRINGER VERLAG, DE, vol. 74, no. 11, 1996, pages 653 - 662, XP002292787, ISSN: 0946-2716 *

Also Published As

Publication number Publication date
WO2004060145A2 (fr) 2004-07-22
AU2003299914A8 (en) 2004-07-29
US20060204495A1 (en) 2006-09-14
US7972848B2 (en) 2011-07-05
WO2004060145A3 (fr) 2004-10-28
US20090311229A1 (en) 2009-12-17
EP1583823A2 (fr) 2005-10-12
AU2003299914A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
IL166332A0 (en) Isolation and identification of t cells
EP1434887A4 (fr) Procede d'isolation de cellules et utilisation correspondante
AU2003273542A8 (en) Methods of identifying and isolating stem cells and cancer stem cells
AU2001270014A1 (en) Compositions for identification and isolation of stem cells
AU7813401A (en) Isolation and use of solid tumor stem cells
IL225633A0 (en) Antibodies against alpha v beta 6 and uses thereof
EP1551447A4 (fr) Anticorps anti-addl et leurs utilisations
PL375691A1 (en) Imidazolopyridines and methods of making and using the same
AU2003230834A8 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
PL375355A1 (en) Novel lipases and uses thereof
EP1687411A4 (fr) Identification et isolation de cellules souches hematopoietiques
EP1554373A4 (fr) Cellules de prepuce humain convenant a la culture de cellules souches
EP1509111A4 (fr) Recipient pour infusion de the anaerobie et son procede d'utilisation
HK1131514A1 (en) Method of isolation and purification
AU2003299914A8 (en) Isolation and identification of cross-reactive t cells
EP1557461A4 (fr) Composition destinee a la culture de cellules souches pluripotentes et utilisation de cette derniere
EP1697715A4 (fr) Identification, isolement et elimination de cellules souches cancereuses
GB2411378B (en) Droplet-deposition related methods and appparatus
IL166063A0 (en) Antibodies and uses thereof
EP1685237A4 (fr) Nouvelles cellules souches multipotentes
AU2003260815A8 (en) Method for the rapid assessment of the presence and viability of bacterial cells and use thereof________________________
GB0119497D0 (en) Expression of modified antibodies in avian cells
AU2003304115A8 (en) Dinoflagellate karlotoxins, methods of isolation and uses thereof
HK1097875A1 (en) Adenovirus-transfected primary cells and methods of pathway mapping
AU2003217743A8 (en) Magnetic immobilization of cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050719

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20051223BHEP

Ipc: C12N 5/00 20060101AFI20050728BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060109

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061103